Clinical trials on CD19-targeted T cell (CTL019) therapy had indicated that sustained remission was associated with the number of lymphocytes with memory phenotype in CLL patients [12]. The gene discussed is CD19; the disease is B-cell chronic lymphocytic leukemia.